Otsuka Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Otsuka Holdings şirketinin toplam hissedar öz sermayesi ¥2,551.1B ve toplam borcu ¥258.9B olup, bu da borç-öz sermaye oranını 10.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥3,597.8B ve ¥1,046.7B dir. Otsuka Holdings 'in FAVÖK'ü ¥401.9B faiz karşılama oranı 32 dur. Şirketin ¥515.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

10.1%

Borç/özkaynak oranı

JP¥258.92b

Borç

Faiz karşılama oranı	32x
Nakit	JP¥515.11b
Eşitlik	JP¥2.55t
Toplam yükümlülükler	JP¥1.05t
Toplam varlıklar	JP¥3.60t

Son finansal sağlık güncellemeleri

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Oct 07

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Mar 15

Recent updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Nov 04

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

Aug 05

Getting In Cheap On Otsuka Holdings Co., Ltd. (TSE:4578) Might Be Difficult

Jul 14

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 02

Is There An Opportunity With Otsuka Holdings Co., Ltd.'s (TSE:4578) 24% Undervaluation?

Apr 20

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Mar 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4578 'nin kısa vadeli varlıkları ( ¥1,434.9B ) kısa vadeli yükümlülüklerini ( ¥747.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: 4578 şirketinin kısa vadeli varlıkları ( ¥1,434.9B ) uzun vadeli yükümlülüklerini ( ¥299.7B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4578 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4578 'nin borç/öz sermaye oranı son 5 yılda 14.9% seviyesinden 10.1% seviyesine düştü.

Borç Kapsamı: 4578 'nin borcu işletme nakit akışı ( 87.6% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 4578 'in borcuna ilişkin faiz ödemeleri EBIT ( 32 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Otsuka Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Recent updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025

Otsuka Holdings Co., Ltd.'s (TSE:4578) Price In Tune With Earnings

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Price target increased by 7.8% to JP¥7,914

Calculating The Intrinsic Value Of Otsuka Holdings Co., Ltd. (TSE:4578)

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

First half dividend of JP¥60.00 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. (TSE:4578) announces an Equity Buyback for 10,000,000 shares, representing 1.84% for ¥50,000 million.

Now 21% undervalued

Otsuka Holdings Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Getting In Cheap On Otsuka Holdings Co., Ltd. (TSE:4578) Might Be Difficult

Price target increased by 9.7% to JP¥6,823

Upcoming dividend of JP¥60.00 per share

Now 22% undervalued

Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026

Now 21% undervalued

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is There An Opportunity With Otsuka Holdings Co., Ltd.'s (TSE:4578) 24% Undervaluation?

Final dividend of JP¥60.00 announced

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Otsuka Holdings Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Revises Dividend for the Full Year Ending December 31, 2023, Payable on March 29 , 2024

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023

Upcoming dividend of JP¥50.00 per share at 1.9% yield

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Now 21% undervalued

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half of Fiscal Year 2023

Otsuka Pharmaceutical Co., Ltd. Announces Positive Results of Phase III Trial in Japan Showing Reduced Agitation in Patients with Alzheimer's Dia Treated with Brexpiprazole

Upcoming dividend of JP¥50.00 per share at 1.8% yield

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Jul 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. Provides Dividend Guidance for Fiscal Year Ending 2023

Otsuka Pharmaceutical Co., Ltd. (Otsuka) Files an Application in Japan for an Additional Indication for Rexulti

Now 23% undervalued after recent price drop

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2022 Results on Feb 14, 2023

Upcoming dividend of JP¥50.00 per share

Now 21% undervalued

Otsuka Medical Devices Co., Ltd. and Recor Medical, Inc. Announce Submission of Application for Pre-Market Approval of the Paradise uRDN to the U.S. FDA

Otsuka Holdings Co., Ltd. Revises Consolidated earnings Guidance for the Fiscal Year Ending December 31, 2022

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Otsuka Holdings Co., Ltd. Revises Consolidated Earrings Guidance for the Fiscal Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month by Otsuka America Pharmaceutical, Inc

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ended June 30, 2022

Price target increased to JP¥4,725

Otsuka Holdings Co., Ltd. to Report Q2, 2022 Results on Jul 29, 2022

Upcoming dividend of JP¥50.00 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter of Fiscal Year Ending December 31, 2022; Provides Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter and Full Year of Fiscal Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Earnings Guidance for the Fiscal Year 2021

Upcoming dividend of JP¥50.00 per share

Third quarter 2021 earnings released: EPS JP¥64.97 (vs JP¥75.52 in 3Q 2020)